Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates

Stem Cells

Volumn 26, Issue 11, 2008, Pages 2974-2980

  Larsen, Stephen R ^a,b   Chng, Keefe ^a   Battah, Fiona ^a   Martiniello Wilks, Rosetta ^a,b   Rasko, John E J ^a,b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c AMGEN INC   (United States)

^d NONE   (Australia)

Author keywords

Cytokines; Granulocyte colony stimulating factor; Mobilization; Nonhuman primate; Peripheral blood stem cells; Thrombopoietin

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD34 SELECTION; CELL POPULATION; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; NONHUMAN; PRIMATE; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL MOBILIZATION; THERAPY EFFECT;

ANIMALS; ANTIGENS, CD34; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; MALE; MICE; PAPIO; POLYETHYLENE GLYCOLS; THROMBOPOIETIN;

ANIMALIA; PRIMATES;

EID: 56249108415     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0560     Document Type: Article

References (42)

1. Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 2001;98:2900-2908.
2. To LB, Haylock DN, Dowse T et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994;84:2930-2939.
3. Brown RA, Adkins D, Goodnough LT et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 1997;15:3067-3074.
4. Villalón L, Odriozola J, Larana JG et al. Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: An analysis of variables concerning mobilisation and engraftment. Hematol J 2000;1:374-381.
5. Yoshida T, Nakamura S, Ohtake S et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 1990;66:1904-1909.
6. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002;28(suppl A):3-6.
7. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 2002;62(suppl 1):89-98.
8. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
9. Molineux G, Kinstler O, Briddell B et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-1734.
10. van Der Auwera P, Platzer E, Xu ZX et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: Comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001;66:245-251.
11. Bruns I, Steidl U, Kronenwett R et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-185.
12. Isidorins A, Tani M, Bonifazi F et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005;90:225-231.
13. Malerba L, Mele A, Leopardi G et al. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Eur J Haematol 2006;76:436-439.
14. Kroschinsky F, Holig K, Poppe-Thiede K et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-1671.
15. Steidl U, Fenk R, Bruns I et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-36.
16. Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995;86:419-431.
17. Ulich TR, del Castillo J, Yin S et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995;86:971-976.
18. Hokom MM, Lacey D, Kinstler OB et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995;86:4486-4492.
19. Basser RL, Rasko JE, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer [erratum in Blood 1997;90:2513]. Blood 1997;89:3118-3128.
20. Rasko JE, Basser RL, Boyd J et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 1997;97:871-880.
21. Linker C, Anderlini P, Herzig R et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003;9:405-413.
22. Gajewski JL, Rondon G, Donato ML et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 2002;8:550-556.
23. Shi PA, Pomper GJ, Metzger ME et al. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. Transfusion 2001;41:1438-1444.
24. Andrews RG, Briddell RA, Knitter GH et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood 1994;84:800-810.
25. Andrews RG, Briddell RA, Knitter GH et al. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995;85:15-20.
26. Harker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833-1844.
27. Harker LA, Marzec UM, Kelly AB et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997;89:155-165.
28. Larsen SR, Kingham JA, Hayward MD et al. Damage to incisors after nonmyeloablative total body irradiation may complicate NOD/SCID models of hemopoietic stem cell transplantation. Comp Med 2006;56:209-214.
29. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981;126:1614-1619.
30. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 1997;89:3919-3924.
31. Pro B, Fayad L, McLaughlin P et al. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:481-485.
32. Morris ES, MacDonald KP, Rowe V et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004;103:3573-3581.
33. Hill GR, Morris ES, Fuery M et al. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006;12:603-607.
34. Moskowitz CH, Stiff P, Gordon MS et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - Results of a phase I/II trial. Blood 1997;89:3136-3147.
35. Weaver A, Chang J, Wrigley E et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998;16:2601-2612.
36. Facon T, Harousseau JL, Maloisel F et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial. Blood 1999;94:1218-1225.
37. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248.
38. Kuter DJ. The promise of thrombopoietins in the treatment of ITP. Clin Adv Hematol Oncol 2005;3:464-466.
39. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628-638.
40. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008;371:395-403.
41. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
42. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004;25:52-60.